- Home
- GENC vs ACRV Comparison
GENC vs ACRV Comparison
Compare GENC & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GENC
- ACRV
- Stock Information
- Founded
- GENC 1894
- ACRV 2018
- Country
- GENC United States
- ACRV United States
- Employees
- GENC N/A
- ACRV N/A
- Industry
- GENC Construction/Ag Equipment/Trucks
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- GENC Industrials
- ACRV Health Care
- Exchange
- GENC Nasdaq
- ACRV Nasdaq
- Market Cap
- GENC 283.7M
- ACRV 247.8M
- IPO Year
- GENC N/A
- ACRV 2022
- Fundamental
- Price
- GENC $21.89
- ACRV $8.57
- Analyst Decision
- GENC
- ACRV Strong Buy
- Analyst Count
- GENC 0
- ACRV 5
- Target Price
- GENC N/A
- ACRV $22.60
- AVG Volume (30 Days)
- GENC 25.1K
- ACRV 48.8K
- Earning Date
- GENC 12-11-2024
- ACRV 11-19-2024
- Dividend Yield
- GENC N/A
- ACRV N/A
- EPS Growth
- GENC 35.02
- ACRV N/A
- EPS
- GENC 1.11
- ACRV N/A
- Revenue
- GENC $113,116,000.00
- ACRV N/A
- Revenue This Year
- GENC N/A
- ACRV N/A
- Revenue Next Year
- GENC N/A
- ACRV N/A
- P/E Ratio
- GENC $19.67
- ACRV N/A
- Revenue Growth
- GENC 5.44
- ACRV N/A
- 52 Week Low
- GENC $13.79
- ACRV $3.19
- 52 Week High
- GENC $24.88
- ACRV $11.90
- Technical
- Relative Strength Index (RSI)
- GENC 62.75
- ACRV 64.34
- Support Level
- GENC $19.63
- ACRV $7.69
- Resistance Level
- GENC $22.67
- ACRV $8.74
- Average True Range (ATR)
- GENC 0.80
- ACRV 0.28
- MACD
- GENC 0.20
- ACRV 0.05
- Stochastic Oscillator
- GENC 76.57
- ACRV 83.76
About GENC Gencor Industries Inc.
Gencor Industries Inc and its subsidiaries is a manufacturer of heavy machinery used in the production of highway construction materials and environmental control equipment. The Company has one reporting segment, equipment for the highway construction industry. The firm's principal products include asphalt plants, combustion systems, hot mix asphalt plants, fluid heat transfer systems, and asphalt pavers.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.